AbbVie's Ludwigshafen facility is situated in the heart of the Rhine Neckar biotechnology region in Western Central Germany, approximately 60 miles south of Frankfurt. The site has been in operation since 1886, and it is a center of excellence for drug product research, development and manufacture. It specializes in innovative solutions for solid dosage forms, including cutting-edge melt extrusion capabilities.
AbbVie's Sligo facility is situated in northwest Ireland, approximately 130 miles from Dublin. It is one of the newest plants in AbbVie's portfolio, having begun operations in 2003. The 110,000 square foot location is a state-of-the-art high containment facility that manufactures a wide range of potent pharmaceuticals. It is capable of handling the highest classifications of potent compounds - with containment levels up to OEB 5 (OEL <1 μg/m3). The Sligo facility is a dedicated cGMP facility for potent active pharmaceutical ingredients and potent drug product are IMB, EU and FDA approved for large-scale commercial manufacture and clinical trial supplies.
AbbVie's Cork facility is situated in the south of Ireland, approximately 165 miles from Dublin. It is a modern drug product manufacturing plant that is highly automated and has an impressive track record of efficient tech transfers. Manufacturing capabilities include tablets, mini-tablets and capsule formulations using innovated technologies. The Cork facility is accredited by regulatory bodies, including the FDA and Irish Medicines Board (IMB) and it is license to distribute to the United States, Canada, Europe and much of the rest of the world.
AbbVie's Campoverde facility is located approximately 22 miles south of Rome in Italy. It is divided into three areas - two for the manufacture of active pharmaceutical ingredients (APIs) and the third dedicated to the formulation and finishing of drug product including liquid dosage. The site has earned certification against ISO 9001, ISO 14001, OSHAS 18001 and DUNI 10167, along with numerous awards for quality and environmental healthy and safety. It is approved by the applicable regulatory bodies to export product to more than 60 countries worldwide.
AbbVie's Lake County facility is situated 40 miles north of Chicago, Illinois. This location is also the headquarters for global operation for AbbVie. The facility manufactures, packaging, and distributes finished drug product, with capabilities including tablets, capsules, liquid-filled capsules, granules, prefilled syringes and oral liquids. The site is inspected and holds accreditation by the FDA, Irish Medicines Board (IMB) and the National Health Surveillance Agency (ANVISA).
AbbVie's North Chicago facility is situated just minutes away from our Lake County headquarters, approximately 40 miles north of Chicago. This location is where our company's pioneering history in pharmaceutical development began. The facility manufactures many of our active pharmaceutical ingredients (APIs) and offers pilot scale to full commercial production. Customers benefit from our extensive scientific and regulatory expertise and excellent track record for reliability. Beyond domestic FDA regulatory accreditation, additional inspections and clearances include the National Health Surveillance Agency Brazil (ANVISA), Japan and Germany.
AbbVie's Worcester facility sits 42 miles west of central Boston, Massachusetts. It is our premier biologics research and development center, and features more than 400,000 square feet of biologics manufacturing space. The facility offers state-of-the-art process design, analytical characterization and cGMP manufacturing for the development and commercialization of biopharmaceutical active pharmacutical ingredients (APIs).
AbbVie's Wyandotte facility is located approximately 10 miles south of Detroit, Michigan and 20 minutes from Detroit Metro Airport. This facility specializes in active pharmaceutical ingredients and intermediates. It has a highly configureable multipurpose train, with an on-site synthesis and characterization laboratory. It also offers the capability for controlled drug security.
AbbVie's Barcelonetai is made up of two facilities situated centrally on the island's northern coastline, approximately 36 miles west of San Juan. One of the two plants at this location produces traditional small molecule drug product. The second plant is dedicated to biologics, active pharmacutical ingredients (APIs) and drug product. It is one of the world's most advanced biopharmaceutical facilities, contributing to the island's growing reputation as a biotech hub. The biologics facility is FDA-approved for commercial manufacturing, features 12,000 L bioreactors and has more than 80 tanks and vessels. The drug product facility offers large-scale tablet and capsule, as well as hot melt extrusion (HME).
AbbVie's Jayuya facility is located in the central highlands of Puerto Rico, approximately 65 miles from San Juan. AbbVie acquired the facility in 2001, and it holds FDA and other regulatory body approvals for the manufactur of potent oral dosage drug product. Capabilities include mixing, compressing and packaging.
AbbVie has state-of-the-art facilities located in North America and Europe, which offer a high degree of flexibility, scale and wide-ranging capabilities for contract manufacturing. These include some of the world’s most technically advanced facilities for their respective specialties – supported by an extensive team of scientific experts. This profile differentiates us and is a major factor in our exceptional reputation for reliability.